GSK Reaches Another Settlement Over Individual Heartburn Drug Lawsuit
Provided by
Dow Jones
By Michael Susin
GSK said it reached a confidential settlement with plaintiff Ronald Kimbrow, resolving a case related to its discontinued heartburn medicine Zantac in the Illinois state court, without disclosing further details.
The British pharmaceutical company on Monday said it will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.
"GSK does not admit any liability in this settlement. The case will now be dismissed as to GSK," it added.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
July 29, 2024 03:49 ET (07:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
United States